Buccal and sublingual vaccine delivery

Abstract Because of their large surface area and immunological competence, mucosal tissues are attractive administration and target sites for vaccination. An important characteristic of mucosal vaccination is its ability to elicit local immune responses, which act against infection at the site of pathogen entry. However, mucosal surfaces are endowed with potent and sophisticated tolerance mechanisms to prevent the immune system from overreacting to the many environmental antigens. Hence, mucosal vaccination may suppress the immune system instead of induce a protective immune response. Therefore, mucosal adjuvants and/or special antigen delivery systems as well as appropriate dosage forms are required in order to develop potent mucosal vaccines. Whereas oral, nasal and pulmonary vaccine delivery strategies have been described extensively, the sublingual and buccal routes have received considerably less attention. In this review, the characteristics of and approaches for sublingual and buccal vaccine delivery are described and compared with other mucosal vaccine delivery sites. We discuss recent progress and highlight promising developments in the search for vaccine formulations, including adjuvants and suitable dosage forms, which are likely critical for designing a successful sublingual or buccal vaccine. Finally, we outline the challenges, hurdles to overcome and formulation issues relevant for sublingual or buccal vaccine delivery.

[1]  P. Wertz,et al.  Cellular and molecular basis of barrier function in oral epithelium. , 1991, Critical reviews in therapeutic drug carrier systems.

[2]  W. Hinrichs,et al.  Needle-free influenza vaccination. , 2010, The Lancet. Infectious diseases.

[3]  Marc B. Brown,et al.  Advances in oral transmucosal drug delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  D. W. Kim,et al.  Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza , 2011, PLoS ONE.

[5]  C. Czerkinsky,et al.  Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood , 2013, Nature Protocols.

[6]  L. Boon,et al.  Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity , 2012, PloS one.

[7]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[8]  J. Mcghee,et al.  Enterotoxin-Based Mucosal Adjuvants Alter Antigen Trafficking and Induce Inflammatory Responses in the Nasal Tract , 2005, Infection and Immunity.

[9]  S. Bertholet,et al.  Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. , 2014, Vaccine.

[10]  S. Cutting,et al.  Mucosal delivery of antigens using adsorption to bacterial spores. , 2010, Vaccine.

[11]  F. Bihl,et al.  Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells , 2013, Mucosal Immunology.

[12]  R. Benoliel,et al.  The distribution of oral mucosal pH values in healthy saliva secretors. , 2006, Oral diseases.

[13]  Xiaoling Li,et al.  Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers. , 2009, Journal of pharmaceutical sciences.

[14]  C. Czerkinsky,et al.  Antigen presentation in the murine oral epithelium , 1996, Immunology.

[15]  C. Maliszewski,et al.  Dendritic Cells Recruitment and In Vivo Priming of CD8+ CTL Induced by a Single Topical or Transepithelial Immunization Via the Buccal Mucosa with Measles Virus Nucleoprotein1 , 2001, The Journal of Immunology.

[16]  Per Brandtzaeg,et al.  Do Salivary Antibodies Reliably Reflect Both Mucosal and Systemic Immunity? , 2007, Annals of the New York Academy of Sciences.

[17]  S. Sugawara,et al.  Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen‐presenting cells in mice , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  C. Czerkinsky,et al.  Sublingual vaccination with influenza virus protects mice against lethal viral infection , 2008, Proceedings of the National Academy of Sciences.

[19]  Wei Zhang,et al.  Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. , 2014, Antiviral research.

[20]  W. Hinrichs,et al.  Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza Vaccine , 2014, The AAPS Journal.

[21]  A. Larsson,et al.  Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  W. Hinrichs,et al.  Pulmonary vaccine delivery: a realistic approach? , 2012, Journal of aerosol medicine and pulmonary drug delivery.

[23]  R. Valenta,et al.  Allergen‐specific immunotherapy: from therapeutic vaccines to prophylactic approaches , 2012, Journal of internal medicine.

[24]  E. Kunkel,et al.  Chemokines in Lymphocyte Trafficking and Intestinal Immunity , 2003, Microcirculation.

[25]  T. Bieber,et al.  Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? , 2008, Allergy.

[26]  D. W. Kim,et al.  Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain , 2012, Virology Journal.

[27]  S. Tzipori,et al.  Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. , 2012, Microbes and infection.

[28]  R. Rappuoli,et al.  Oral Spray Immunization May Be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies but not Nasal Mucosal or Cellular Immunity , 2006, Scandinavian journal of immunology.

[29]  W. Pw,et al.  Cellular and molecular basis of barrier function in oral epithelium. , 1991 .

[30]  C. Oeser,et al.  Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers , 2012, PloS one.

[31]  G. Kobinger,et al.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. , 2012, Molecular pharmaceutics.

[32]  Bella,et al.  The murine buccal mucosa is an inductive site for priming class I‐restricted CD8+ effector T cells in vivo , 1998, Clinical and experimental immunology.

[33]  W. Hinrichs,et al.  Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities , 2008, Pharmaceutical Research.

[34]  Carl-Fredrik Flach,et al.  Sublingual Immunization Protects against Helicobacter pylori Infection and Induces T and B Cell Responses in the Stomach , 2010, Infection and Immunity.

[35]  Chih-Chien Wang,et al.  Neonatal Sublingual Vaccination with Salmonella Proteins and Adjuvant Cholera Toxin or CpG Oligodeoxynucleotides Induces Mucosal and Systemic Immunity in Mice , 2008, Journal of pediatric gastroenterology and nutrition.

[36]  A. Amalfitano,et al.  Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity , 2010, Clinical and Vaccine Immunology.

[37]  C. Cutler,et al.  Dendritic Cells at the Oral Mucosal Interface , 2006, Journal of dental research.

[38]  W. Lo,et al.  Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[39]  L. Eusebi,et al.  Merkel Cells in the Oral Mucosa , 2006, International journal of surgical pathology.

[40]  A. Hovav Dendritic cells of the oral mucosa , 2013, Mucosal Immunology.

[41]  Jason T McConville,et al.  Manufacture and characterization of mucoadhesive buccal films. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  S. Dewhurst,et al.  Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. , 2011, Vaccine.

[43]  A. Louise,et al.  Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. , 2008, The Journal of allergy and clinical immunology.

[44]  M. Maddaloni,et al.  Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. , 2012, International immunology.

[45]  Carl-Fredrik Flach,et al.  A Double Mutant Heat-Labile Toxin from Escherichia coli, LT(R192G/L211A), Is an Effective Mucosal Adjuvant for Vaccination against Helicobacter pylori Infection , 2013, Infection and Immunity.

[46]  M. Prausnitz,et al.  Measles vaccination using a microneedle patch. , 2013, Vaccine.

[47]  W. Jiskoot,et al.  2 Rational design of nasal vaccines , 2011 .

[48]  P. Brandtzaeg Function of Mucosa-Associated Lymphoid Tissue in Antibody Formation , 2010, Immunological investigations.

[49]  Elly van Riet,et al.  Advances in transcutaneous vaccine delivery: do all ways lead to Rome? , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[50]  David Chen Formulation of HPV Dry Powder Wafers for Sublingual Vaccination , 2012 .

[51]  S. Tzipori,et al.  Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. , 2011, Vaccine.

[52]  R. Cox,et al.  Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c-di-GMP , 2011, PloS one.

[53]  G. Del Giudice,et al.  Persistence of mucosal and systemic immune responses following sublingual immunization. , 2010, Vaccine.

[54]  Young Bong Kim,et al.  Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. , 2010, Vaccine.

[55]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[56]  M. Prausnitz,et al.  Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[57]  J. D. Paccez,et al.  Gut Adhesive Bacillus subtilis Spores as a Platform for Mucosal Delivery of Antigens , 2014, Infection and Immunity.

[58]  Jun Chang,et al.  Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant , 2012, PloS one.

[59]  Jun Chang,et al.  Mucosal Immunization with Recombinant Adenovirus Encoding Soluble Globular Head of Hemagglutinin Protects Mice Against Lethal Influenza Virus Infection , 2013, Immune network.

[60]  C. Czerkinsky,et al.  CCR7-CCL19/CCL21-Regulated Dendritic Cells Are Responsible for Effectiveness of Sublingual Vaccination1 , 2009, The Journal of Immunology.

[61]  C. Czerkinsky,et al.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. , 2007, Vaccine.

[62]  S. Gerber,et al.  Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with Escherichia coli Heat-Labile Enterotoxin Mutant R192G or CpG DNA , 2001, Journal of Virology.

[63]  A. Haase,et al.  Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route , 2012, Clinical and Vaccine Immunology.

[64]  J. Robinson,et al.  Drug delivery via the mucous membranes of the oral cavity. , 1992, Journal of pharmaceutical sciences.

[65]  Carl-Fredrik Flach,et al.  Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice. , 2012, Vaccine.

[66]  B. Ferko,et al.  Sublingual Immunization with a Live Attenuated Influenza A Virus Lacking the Nonstructural Protein 1 Induces Broad Protective Immunity in Mice , 2012, PloS one.

[67]  J. Holmgren,et al.  Vaccines against mucosal infections. , 2012, Current opinion in immunology.

[68]  V. Ferro,et al.  Optimizing efficacy of mucosal vaccines , 2012, Expert review of vaccines.

[69]  J. Clements,et al.  Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant , 2011, Clinical and Vaccine Immunology.

[70]  J. Katz,et al.  Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. , 2002, Vaccine.

[71]  W. Hinrichs,et al.  Towards tailored vaccine delivery: needs, challenges and perspectives. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[72]  Jun Chang,et al.  Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection , 2013, PloS one.

[73]  N. Lycke,et al.  Immunity against a Chlamydia infection and disease may be determined by a balance of IL‐17 signaling , 2014, Immunology and cell biology.

[74]  C. Czerkinsky,et al.  Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. , 2012, Current topics in microbiology and immunology.

[75]  C. Czerkinsky,et al.  Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. , 2010, Vaccine.

[76]  Y. Chu,et al.  Effect of Neonatal Sublingual Vaccination with Native or Denatured Ovalbumin and Adjuvant CpG or Cholera Toxin on Systemic and Mucosal Immunity in Mice , 2008, Scandinavian journal of immunology.

[77]  R. Shattock,et al.  Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice , 2012, PloS one.

[78]  C. Czerkinsky,et al.  "PERFEXT": a direct method for quantitative assessment of cytokine production in vivo at the local level. , 1997, Research in immunology.

[79]  J. Schiller,et al.  Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection1 , 2009, The Journal of Immunology.

[80]  A. Larsson,et al.  The Impact of Dose and Solubility of Additives on the Release from HPMC Matrix Tablets—Identifying Critical Conditions , 2009, Pharmaceutical Research.

[81]  S. Ozawa,et al.  Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity. , 2011, Health affairs.

[82]  R. Malley,et al.  Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell Vaccine , 2010, Clinical and Vaccine Immunology.

[83]  C. Czerkinsky,et al.  Sublingual ‘Oral Tolerance’ Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Regulatory T Cells that Induce Apoptosis and Depletion of Effector T Cells , 2007, Scandinavian journal of immunology.